This inventor holds 1 USPTO granted patent. Top assignee: Astrazeneca Ab. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Sten Nilsson-lill: Innovator in Cancer Treatment
Introduction
Sten Nilsson-lill is an inventor based in Södertälje, Sweden. He is known for his contributions to the field of cancer treatment through innovative chemical compounds. Although he currently holds no granted patents, his work in developing potential therapies is noteworthy.
Latest Patent Applications
Sten Nilsson-lill's latest patent application is titled "SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER." This application discloses certain substituted pyrazine-2-carboxamides of Formula (I), along with their pharmaceutically acceptable salts. The compounds are identified as inhibitors of hematopoietic progenitor kinase 1 (HPK1), making them particularly useful in the treatment or prophylaxis of cancer.
Conclusion
Sten Nilsson-lill's innovative approach to cancer treatment through his latest patent application highlights the potential of new compounds in medical therapy. His work may pave the way for future advancements in cancer treatment.